性感染症(STD)治療の世界市場2019-2023

◆英語タイトル:Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023
◆商品コード:IRTNTR31124
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年3月29日
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥327,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、性感染症(STD)治療の世界市場について調査・分析し、市場概要、市場環境、性感染症(STD)治療市場規模、種類別(ウイルス感染 、菌感染症、その他感染)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・性感染症(STD)治療の世界市場概要
・性感染症(STD)治療の世界市場環境
・性感染症(STD)治療の世界市場動向
・性感染症(STD)治療の世界市場規模
・性感染症(STD)治療の世界市場:業界構造分析
・性感染症(STD)治療の世界市場:種類別(ウイルス感染 、菌感染症、その他感染)
・性感染症(STD)治療の世界市場:地域別市場規模・分析
・性感染症(STD)治療の北米市場規模・予測
・性感染症(STD)治療のヨーロッパ・中東・アフリカ市場規模・予測
・性感染症(STD)治療のアジア太平洋市場規模・予測
・性感染症(STD)治療の主要国分析
・性感染症(STD)治療の世界市場:意思決定フレームワーク
・性感染症(STD)治療の世界市場:成長要因、課題
・性感染症(STD)治療の世界市場:競争環境
・性感染症(STD)治療の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
The increasing prevalence of STDs is one of the key factors expected to trigger the market’s growth in the forthcoming years. STDs are rising in the emerging and advanced economies, resulting in the rising demand for drugs and therapies for treating these chronic illnesses. The cases of these incidences has increased considerably in the recent years owing to the transmission of different bacteria, viruses, and parasites during sexual contact. As a result, the increasing prevalence of STDs will further propel the demand for drugs and therapies, in turn, contributing significantly to the STD treatment market growth during the forecast period. Technavio’s analysts have predicted that the sexually transmitted diseases (STD) treatment market will register a CAGR of more than 4% by 2023.
Market Overview
Approval of drugs and a strong pipeline
One of the growth drivers of the global sexually transmitted diseases (STD) treatment market is the approval of drugs and a strong pipeline. With the increase in prevalence and incidence of STDs, market players are focused on the development of therapies to treat these diseases. The market has witnessed new drug approvals, which will drive the market during the forecast period.
Social stigma associated with STDs
One of the challenges in the growth of the global sexually transmitted diseases (STD) treatment market is the social stigma associated with STDs. The social stigma associated with STDs can lead to reduced screening, prevention, and care, thereby hindering the growth of the market.
For the detailed list of factors that will drive and challenge the growth of the sexually transmitted diseases (STD) treatment market during 2019-2023, view our report.
Competitive Landscape
The market appears to be moderately fragmented with the presence of several market players. Many government organizations are collaborating with commercial companies to develop HIV vaccines. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Viral infections – Market size and forecast 2018-2023
• Bacterial infections – Market size and forecast 2018-2023
• Other infections – Market size and forecast 2018-2023
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Market trends
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Type – Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Viral infections – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Viral infections – Year-over-year growth 2019-2023 (%)
Exhibit 21: Bacterial infections – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Bacterial infections – Year-over-year growth 2019-2023 (%)
Exhibit 23: Other infections – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Other infections – Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America – Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Pipeline drugs for STDs
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Some of the HIV vaccines under clinical trials
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Bristol-Myers Squibb Company – Vendor overview
Exhibit 48: Bristol-Myers Squibb Company – Business segments
Exhibit 49: Bristol-Myers Squibb Company – Organizational developments
Exhibit 50: Bristol-Myers Squibb Company – Geographic focus
Exhibit 51: Bristol-Myers Squibb Company – Key offerings
Exhibit 52: Gilead Sciences, Inc. – Vendor overview
Exhibit 53: Gilead Sciences, Inc. – Business segments
Exhibit 54: Gilead Sciences, Inc. – Organizational developments
Exhibit 55: Gilead Sciences, Inc. – Geographic focus
Exhibit 56: Gilead Sciences, Inc. – Key offerings
Exhibit 57: GlaxoSmithKline plc – Vendor overview
Exhibit 58: GlaxoSmithKline plc – Business segments
Exhibit 59: GlaxoSmithKline plc – Organizational developments
Exhibit 60: GlaxoSmithKline plc – Geographic focus
Exhibit 61: GlaxoSmithKline plc – Segment focus
Exhibit 62: GlaxoSmithKline plc – Key offerings
Exhibit 63: Johnson & Johnson Services, Inc. – Vendor overview
Exhibit 64: Johnson & Johnson Services, Inc. – Business segments
Exhibit 65: Johnson & Johnson Services, Inc. – Organizational developments
Exhibit 66: Johnson & Johnson Services, Inc. – Geographic focus
Exhibit 67: Johnson & Johnson Services, Inc. – Segment focus
Exhibit 68: Johnson & Johnson Services, Inc. – Key offerings
Exhibit 69: Merck & Co., Inc. – Vendor overview
Exhibit 70: Merck & Co., Inc. – Business segments
Exhibit 71: Merck & Co., Inc. – Organizational developments
Exhibit 72: Merck & Co., Inc. – Geographic focus
Exhibit 73: Merck & Co., Inc. – Segment focus
Exhibit 74: Merck & Co., Inc. – Key offerings
Exhibit 75: Validation techniques employed for market sizing



【掲載企業】

Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[性感染症(STD)治療の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆